Home Cart Sign in  
Chemical Structure| 123855-51-6 Chemical Structure| 123855-51-6

Structure of N-Boc-4-piperidinemethanol
CAS No.: 123855-51-6

Chemical Structure| 123855-51-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Berg, Kaja ; Hegde, Pooja ; Pujari, Venugopal ; Brinkmann, Marzena ; Wilkins, David Z. ; Parish, Tanya , et al.

Abstract: The electron transport chain (ETC) in the cell membrane consists of a series of redox complexes that transfer electrons from electron donors to acceptors and couples this electron transfer with the transfer of protons (H+) across a membrane. This process generates proton motive force which is used to produce ATP and a myriad of other functions and is essential for the long-term survival of Mycobacterium tuberculosis (Mtb), the causative organism of tuberculosis (TB), under the hypoxic conditions present within infected granulomas. Menaquinone (MK), an important carrier molecule within the mycobacterial ETC, is synthesized de novo by a cluster of enzymes known as the classic/canonical MK biosynthetic pathway. MenA (1,4-dihydroxy-2-naphthoate prenyltransferase), the antepenultimate enzyme in this pathway, is a verified target for TB therapy. In this study, we explored structure-activity relationships of a previously discovered MenA inhibitor scaffold, seeking to improve potency and drug disposition properties. Focusing our campaign upon three molecular regions, we identified two novel inhibitors with potent activity against MenA and Mtb (IC50 = 13-22 μM, GIC50 = 8-10 μM). These analogs also displayed substantially improved pharmacokinetic parameters and potent synergy with other ETC-targeting agents, achieving nearly complete sterilization of Mtb in combination therapy within two weeks in vivo. These new inhibitors of MK biosynthesis present a promising new strategy to curb the continued spread of TB.

Keywords: 1,4-dihydroxy-2-naphthoate prenyltransferase ; MenA ; MenA inhibitors ; Menaquinone ; Mtb ; Mycobacterium tuberculosis ; Piperidine derivatives ; SAR

Alternative Products

Product Details of [ 123855-51-6 ]

CAS No. :123855-51-6
Formula : C11H21NO3
M.W : 215.29
SMILES Code : O=C(N1CCC(CO)CC1)OC(C)(C)C
MDL No. :MFCD02094488
InChI Key :CTEDVGRUGMPBHE-UHFFFAOYSA-N
Pubchem ID :2764081

Safety of [ 123855-51-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 123855-51-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 15
Num. arom. heavy atoms 0
Fraction Csp3 0.91
Num. rotatable bonds 4
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 62.56
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

49.77 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.66
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.17
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.24
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.15
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.93
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.43

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.65
Solubility 4.84 mg/ml ; 0.0225 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.81
Solubility 3.33 mg/ml ; 0.0155 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.11
Solubility 16.7 mg/ml ; 0.0774 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.78 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.12

Application In Synthesis of [ 123855-51-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 123855-51-6 ]

[ 123855-51-6 ] Synthesis Path-Downstream   1~11

  • 1
  • [ 67247-13-6 ]
  • [ 123855-51-6 ]
  • [ 776296-04-9 ]
  • 2
  • [ 1137475-57-0 ]
  • [ 123855-51-6 ]
  • [ 1137476-28-8 ]
YieldReaction ConditionsOperation in experiment
62% N-Boc-4-piperidinemethanol (860 mg, 4.0 mmol) was added to a suspension of 60% sodium hydride (160 mg, 4.0 mmol) in DMF (40 mmol) at room temperature. After 20 minutes, <strong>[1137475-57-0]2-bromo-4-chloro-5-nitropyridine</strong> (949 mg, 4.0 mmol) was added in one portion, and the resulting mixture was stirred overnight at room temperature. The mixture was diluted with ether and washed with water. The aqueous phase was extracted with ether. The combined organic phases were washed with water and brine, then dried (Na2SO4) and concentrated. Silica column chromatography, eluting with 20% ethyl acetate - hexane, gave tert-butyl 4-((2-bromo-5-nitropyridin-4-yloxy)methyl)piperidine-1-carboxylate (789 mg, 62%) as a viscous, pale yellow oil which solidified on standing.1H NMR (CDCI3, 400MHz) delta 8.80 (s, 1H), 7.20 (s, 1H)7 4.05-4.15 (m, 2H), 4.00 (d, 2H, J = 6.3 Hz), 2.75-2.85 (m, 2H), 2.10 (m, 1H), 1.80-1.90 (m, 2H), 1.45 (s, 9H), 1.20-1.30 (m, 2H). LCMS (1 ) Rt = 2.45 min; m/z (ESI+) 316, 318 (MH+),
  • 4
  • [ 1354961-13-9 ]
  • [ 123855-51-6 ]
  • tert-butyl 4-((4-(tert-butoxycarbonyl)-2-chloro-5-fluorophenoxy)-methyl)piperidine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
60% With potassium tert-butylate; In dimethyl sulfoxide; at 20℃; for 1h; Potassium tert-butoxide (6.2 g, 55.6 mmol) was added to a solution of tert-butyl 4-(hydroxymethyl) piperidine-1-carboxylate (10.0 g, 46.3 mmol) and tert-butyl 5-chloro-2, 4-difluorobenzoate (12.6 g, 50.9 mmol) in DMSO (200 mL) . After stirring at room temperature for1h, the reaction mixture was diluted with water (500 mL) and extracted with EtOAc (200 mL × 3) . The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (eluting with petroleum ether/ethyl acetate, from 20/1 to 5/1) to afford the target compound (12.3 g, yield: 60) as a pale yellowliquid. LCMS (ESI) m/z: 331.9. [M-111]+.
60% With potassium tert-butylate; In dimethyl sulfoxide; at 20℃; for 1h;Inert atmosphere; Step 1 (0232) Potassium tert-butoxide (6.2 g, 55.6 mmol) was added to a solution of tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (10.0 g, 46.3 mmol) and <strong>[1354961-13-9]tert-butyl 5-chloro-2,4-difluorobenzoate</strong> (12.6 g, 50.9 mmol) in DMSO (200 mL). After stirring at room temperature for 1 h, the reaction mixture was diluted with water (500 mL) and extracted with EtOAc (200 mL×3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (eluting with petroleum ether/ethyl acetate, from 20/1 to 5/1) to afford the target compound (12.3 g, yield: 60%) as a pale yellow liquid. LCMS (ESI) m/z: 331.9. [M-111]+.
  • 5
  • [ 123855-51-6 ]
  • [ 581060-27-7 ]
  • 6
  • [ 123855-51-6 ]
  • [ 183170-69-6 ]
  • 7
  • [ 13589-72-5 ]
  • [ 123855-51-6 ]
  • tert-butyl 4-((4-chloro-2-cyanophenoxy)methyl)piperidine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
17 g With di-isopropyl azodicarboxylate; triphenylphosphine; In tetrahydrofuran; at 20℃; for 24h; 15 g of <strong>[13589-72-5]5-chloro-2-hydroxybenzonitrile</strong> was added to 180 ml of tetrahydrofuran, and 19 g of tert-butyl 4- (hydroxymethyl) piperidine-1-carboxylate, 42 g of triphenylphosphine, 35 g of bis Isopropyl acetate, stirred at room temperature for 24 hours, concentrated and the residue was chromatographed on a silica gel column to obtain 17 g of tert-butyl 4 - ((4-chloro-2-cyanophenoxy) methyl) piperidine-1-carboxylate.
With di-isopropyl azodicarboxylate; triphenylphosphine; In tetrahydrofuran; toluene; at 0 - 35℃; for 12h; To a solution of <strong>[13589-72-5]5-chloro-2-hydroxybenzonitrile</strong> (2.50 g), tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate(3.50 g) and triphenylphosphine (5.12 g) in THF (50 mL) was added 1.9 M DIAD (toluene solution, 10.3 mL) at 0C, andthe reaction mixture was stirred at room temperature for 12 hr. The reaction mixture was concentrated, and the residuewas purified by silica gel column chromatography (ethyl acetate/hexane) to give tert-butyl 4-((4-chloro-2-cyanophenoxy)methyl)piperidine-1-carboxylate as a crude product.
  • 8
  • [ 52764-11-1 ]
  • [ 123855-51-6 ]
  • tert-butyl 4-(((2,6-dichloropyridin-3-yl)oxy)methyl)piperidine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With di-isopropyl azodicarboxylate; triphenylphosphine; In tetrahydrofuran; toluene; at 0 - 35℃; for 8h; To a solution of <strong>[52764-11-1]2,6-dichloropyridin-3-ol</strong> (1.06 g), tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (1.39 g)and triphenylphosphine (2.03 g) in THF (30 mL) was added 1.9 M DIAD (toluene solution, 4.08 mL) at 0C, and thereaction mixture was stirred at room temperature for 8 hr. The reaction mixture was concentrated, and the residue waspurified by silica gel column chromatography (ethyl acetate/hexane) to give tert-butyl 4-(((2,6-dichloropyridin-3-yl)oxy)methyl)piperidine-1-carboxylate as a crude product
  • 9
  • [ 123855-51-6 ]
  • [ 597563-39-8 ]
  • 10
  • [ 32315-10-9 ]
  • [ 145742-50-3 ]
  • [ 123855-51-6 ]
  • tert-butyl 4-[(2-chloro-4-formyl-5-methoxyphenyl)carbamoyloxymethyl]piperidine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
74% <strong>[145742-50-3]4-amino-5-chloro-2-methoxybenzaldehyde</strong> (3a) (6.9 g, 37.2 mmol) was dissolved in toluene (100 ml), to which triphosgene (5.51 g, 18.6 mmol) was added, followed by a reaction at 120C for 2 hours, and the resultant was concentrated to obtain Reaction solution 1. Tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (2a) (2.00 g, 9.29 mmol) was dissolved in tetrahydrofuran (50 ml), to which Reaction solution 1 and then triethylamine (3.76 g, 37.2 mmol) were added, followed by a reaction at 70C for 2 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether (v/v) = 1:9 to 3:7) to give yellow oily tert-butyl 4-[(2-chloro-4-formyl-5-methoxy-phenyl)carbamoyloxymethyl]piperidine-1-carboxyl ate (3b) (2.2 g, yield: 74%). 1H NMR (400 MHz, CDCl3) delta 10.29 (s, 1H), 8.05 (s, 1H), 7.83 (s, 1H), 7.41 (s, 1H), 4.16 (d, 2H), 4.09 (d, 2H), 3.95 (s, 3H), 2.73 (m, 2H), 1.96 - 1.83 (m, 1H), 1.75 (d, 2H), 1.46 (s, 9H), 1.32 - 1.18 (m, 2H). LCMS m/z =449.3 [M+23].
  • 11
  • [ 123855-51-6 ]
  • [ 4983-28-2 ]
  • [ 1314391-51-9 ]
YieldReaction ConditionsOperation in experiment
With di-isopropyl azodicarboxylate; triphenylphosphine; In tetrahydrofuran; at 0 - 20℃; for 12h;Inert atmosphere; General procedure: Compound 3-(dimethylamino)propan-1-ol (825.28 mg, 8 mmol) and triphenylphosphine (2.517 g, 9.6mmol) were added successively to a suspension of 19 (1.044 g, 8 mmol) in THF (15 mL) under nitrogen.A solution of DIAD (1.67 g, 9.6 mmol) in THF (2 mL) was then slowly added dropwise with ice cooling.The resultant solution was stirred at room temperature for 12 hours. The aqueous phase wasextracted with dichloromethane (40 mL 3). The combined organic layer was washed with H2O (40 mL)and brine (20 mL), and then dried over anhydrous Na2SO4, filtered and evaporated in vacuo. Theresidue was purified by flash chromatography over silica gel (DCM/MeOH = 40:110:1) to give 20a.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 123855-51-6 ]

Alcohols

Chemical Structure| 236406-21-6

A123210 [236406-21-6]

1-Boc-4-(Hydroxymethyl)-4-methylpiperidine

Similarity: 1.00

Chemical Structure| 236406-33-0

A137220 [236406-33-0]

tert-Butyl 4-(2-hydroxyethyl)-4-methylpiperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 89151-44-0

A150552 [89151-44-0]

N-Boc-4-Piperidineethanol

Similarity: 0.98

Chemical Structure| 156185-63-6

A165055 [156185-63-6]

tert-Butyl 4-(3-hydroxypropyl)piperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 116574-71-1

A166519 [116574-71-1]

tert-Butyl 3-(hydroxymethyl)piperidine-1-carboxylate

Similarity: 0.96

Amides

Chemical Structure| 236406-21-6

A123210 [236406-21-6]

1-Boc-4-(Hydroxymethyl)-4-methylpiperidine

Similarity: 1.00

Chemical Structure| 236406-33-0

A137220 [236406-33-0]

tert-Butyl 4-(2-hydroxyethyl)-4-methylpiperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 89151-44-0

A150552 [89151-44-0]

N-Boc-4-Piperidineethanol

Similarity: 0.98

Chemical Structure| 156185-63-6

A165055 [156185-63-6]

tert-Butyl 4-(3-hydroxypropyl)piperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 116574-71-1

A166519 [116574-71-1]

tert-Butyl 3-(hydroxymethyl)piperidine-1-carboxylate

Similarity: 0.96

Related Parent Nucleus of
[ 123855-51-6 ]

Piperidines

Chemical Structure| 236406-21-6

A123210 [236406-21-6]

1-Boc-4-(Hydroxymethyl)-4-methylpiperidine

Similarity: 1.00

Chemical Structure| 236406-33-0

A137220 [236406-33-0]

tert-Butyl 4-(2-hydroxyethyl)-4-methylpiperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 89151-44-0

A150552 [89151-44-0]

N-Boc-4-Piperidineethanol

Similarity: 0.98

Chemical Structure| 156185-63-6

A165055 [156185-63-6]

tert-Butyl 4-(3-hydroxypropyl)piperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 116574-71-1

A166519 [116574-71-1]

tert-Butyl 3-(hydroxymethyl)piperidine-1-carboxylate

Similarity: 0.96